Does Professional CGM Decrease the Economic Burden of T2D?
Professional continuous glucose monitoring can significantly reduce the economic burden of type 2 diabetes.
Type 1 Diabetes 2017
Novel Adaptive Artificial Pancreas Improves HbA1c and Reduces Hypoglycemia
Adapting open-loop settings that are used by the artificial pancreas algorithm is easily understandable and transparent to both patients and physicians.
Efficacy of CGM in Preterm Infants of Mothers With Diabetes
Real-time continuous glucose monitoring systems are comparable to traditional blood glucose monitoring methods in preterm infants.
EASD, ADA Recommendations Aimed at Improving Safety, Efficacy of CGM
With this statement, researchers hope to improve safety and efficacy outcomes, advance technology, and improve patient quality of life and health outcomes.
Insulin Pump Associated With Fewer Complications Than Injections in Children, Adolescents
Although the incidence of severe hypoglycemia has decreased while insulin pump use has increased, a causal relationship has not been established between insulin administration methods and risk of complications from diabetes.
Managing Type 2 Diabetes: The Impact of Secure Patient-Provider Messaging
Secure messaging presents an opportunity for patients and healthcare providers to collaborate on self-management issues like glycemic control, diet, and exercise.
Peptide Immunotherapy for Type 1 Diabetes: A Promising New Treatment
Peptide immunotherapy may offer a personalized approach to modulating the immune response in persons with type 1 diabetes.
No Fingerstick Necessary: FDA Approves Novel CGM System for Diabetes
New monitoring system involves the placement of a small sensor wire beneath the skin surface to continuously monitor glucose levels.
Reversing Type 1 Diabetes May Be Possible With Tuberculosis Vaccine
Data from a phase 1 study was presented at the 2017 ADA Scientific Sessions.
CVD Risk Management in Type 1 Diabetes Improved With Metformin
Although metformin did not improve glycemic control in patients with type 1 diabetes, the treatment did improve cardiovascular disease risk management.
